IN8bio Presents New INB-100 Data, at EBMT 2023, Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients
(24/7 MARKET NEWS) – IN8bio, Inc. (NASDAQ:INAB) presented new positive data from the Phase 1 investigator-sponsored trial of INB-100 in leukemia patients, at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), showing that 100% of evaluable patients (n=7) treated with INB-100 remained alive, progression-free, and in durable complete remission (CR) as of April 21, 2023, indicating the curative potential of INB-100 for high-risk or relapsed AML and other hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT).
IN8bio is trading at $1.15, up $0.09 (+8.49%), on 29K shares traded.
Its 52-week range is $1.02 to 3.56. Today’s news and price move may signal a potential trend reversal. If so, it should retrace to the $1.42 inflection point, maybe much higher.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.